Cronos Group price target raised to $2.50 from $2 at BofA

BofA analyst Lisa Lewandowski raised the firm’s price target on Cronos Group to $2.50 from $2 and keeps an Underperform rating on the shares. The firm sees recent developments in German medical cannabis prescriptions, upcoming regulatory/prescription changes in Israel, and Canadian panel recommendations as a plus, but cautions investors to not overreact to these changes/proposals, as history has proved that progress in the cannabis world moves at a much slower pace than investors might want and not in a straight line.